In patients with squamous cell carcinoma and adenocarcinoma who were administered paclitaxel liposome based chemotherapy plus PD-1/PD-L1 inhibitor as first-line therapy, median PFS were 11 months (95% CI, 6.3–15.7) and 9.3 months (95% CI, 4.6–14.0), respectively (Fig. 1C). This evidence concerns the gene CD274 and adenocarcinoma.